Hologic delivered Q3 FY2025 revenue of $1.024 billion (0.4% YoY growth) and non-GAAP EPS of $1.08 (1.9% YoY), beating the high end of guidance on both metrics. Management characterized the quarter as one of 'progress,' citing sequential improvement in the Breast Health segment and better-than-expected performance in Diagnostics and Surgical. The company raised full-year FY2025 guidance to $4.081-$4.091 billion in revenue and $4.23-$4.26 in EPS, driven by strong execution and successful mitigation of tariff headwinds. Looking ahead to FY2026, management expressed confidence in returning to mid-single-digit organic growth, supported by new product launches like Envision and the integration of Endomag.
| Metric | Value | Change |
|---|---|---|
| Total Revenue | $1.024 billion | +0.4% YoY |
| Non-GAAP EPS | $1.08 | +1.9% YoY |
| Diagnostics Revenue | $448.9 million | +0.9% Reported / +2.9% Organic ex-COVID |
| Breast Health Revenue | $365.2 million | -5.8% Reported |
| Surgical Revenue | $178.4 million | +6.3% Reported / +1.2% Organic ex-Gynesonics |
| Non-GAAP Gross Margin | 60.3% | -80 bps YoY |
| Non-GAAP Operating Margin | 30.1% | -110 bps YoY |
| Operating Cash Flow | $343 million | N/A |
| Tariff Impact (Q3) | $1.4 million | Mitigated |
Hologic's Breast Health segment is showing tangible signs of stabilization and recovery, a critical pivot point for the stock. Management reported that while revenue declined 5.8% YoY, it grew sequentially and beat internal expectations, driven by a 31.8% surge in interventional products. The acquisition of Endomag is immediately accretive, contributing nearly $20 million in revenue in Q3 with healthy margins, validating the M&A strategy. Management expects Breast Health to return to slight top-line growth in Q4, signaling that the worst of the capital equipment headwinds has passed.
The company is successfully navigating a complex tariff environment, which speaks to operational resilience. Initial estimates projected a $20-$25 million quarterly headwind, but management mitigated this by roughly 50% through supply chain changes, reducing the impact to $10-$12 million per quarter. This mitigation effort helped preserve gross margins (60.3%) and operating margins (30.1%), which remain best-in-class. This ability to adapt to external shocks provides confidence in the margin profile heading into FY2026.
Innovation remains a core growth driver, with the launch of Genius AI Detection PRO and the upcoming release of the next-generation Envision mammography system in 2026. The new AI software offers a 24% reduction in reading time, addressing radiologist labor shortages and improving throughput. Management indicated that Envision will be a meaningful driver in late 2026 and beyond, suggesting a new product cycle is imminent to reinvigorate the installed base of roughly 2,000 legacy gantries.
The Diagnostics segment is evolving into a more diversified and stable growth engine. While facing headwinds in China and Africa, the core business remains robust, with Panther utilization hitting all-time highs. The strategy to expand the Panther Fusion menu beyond respiratory testing into GI and hospital-acquired infections (launching late FY26/early FY27) positions Hologic to capture a larger share of the lab wallet. The BV/CV/TV assay continues to perform well, now ranking as the company's second-largest assay.
International expansion is becoming a significant offset to domestic challenges, particularly in the Surgical franchise. International sales grew 24.8% in the quarter, driven by new reimbursement pathways and market expansion. Products like NovaSure are delivering double-digit growth overseas, highlighting the significant whitespace available in global women's health. This geographic diversification reduces reliance on the U.S. market and provides a buffer against specific regional policy changes.
Significant exposure to China remains a persistent vulnerability, with revenue in the region dropping more than 50% YoY to less than $10 million in the quarter. Management cited a 'challenging operating environment' and geopolitical turmoil, noting that these headwinds will persist into the first half of FY2026. This rapid deterioration in a key market raises concerns about the long-term viability of Hologic's footprint in China and the potential for further revenue drag.
The Skeletal Health division's explosive 62.1% growth in Q3 is largely attributed to fulfilling pent-up demand following a shipping hold, creating a tough comparison for future periods. Management explicitly warned that Skeletal revenue will be lower in FY2026 as this demand is satisfied and the company discontinues the low-margin Fluoroscan product ($18 million revenue impact). Investors should not extrapolate the current Skeletal performance into future growth rates.
While management raised guidance, the overall revenue growth for the quarter was a modest 0.4%, and full-year growth implies a relatively flat performance year-over-year. The heavy lifting for the stock price relies on a successful pivot to growth in FY2026. If the anticipated recovery in Breast Health or the new product cycle fails to materialize as expected, the valuation multiple could compress given the current lack of top-line momentum.
Tariff headwinds, while mitigated, are not disappearing and will structurally impact margins in FY2026. Management expects $10-$12 million in quarterly tariff expenses next year, representing a roughly 100 basis point headwind to gross margin compared to FY2025 levels. This persistent cost pressure will require continued operational excellence or pricing power to maintain the company's historically high margin profile.
Management noted that the HIV testing business in Africa is facing 'funding cuts to U.S. aid,' which has impacted revenue. They expect this business to drop to 'de minimis numbers' in FY2026. This creates a revenue hole that the core business must fill, adding pressure on the molecular diagnostics team to deliver growth in other areas like vaginitis and respiratory testing to offset the decline in this historically stable franchise.
Overall: Management displayed a confident and assured demeanor, frequently using the word 'progress' to describe the quarter's results. They acknowledged recent 'speed bumps' but firmly stated these are behind them, projecting optimism for a return to growth in Q4 and acceleration into FY2026. The tone shifted from defensive in previous quarters to proactive, highlighting specific operational wins and successful mitigation of external risks like tariffs.
Confidence: HIGH - Management raised guidance, provided specific details on commercial execution improvements, and offered concrete numbers regarding tariff mitigation. Their language was forward-looking and decisive, particularly regarding the Breast Health recovery and the integration of recent acquisitions.
$1.03 billion - $1.04 billion
$1.09 - $1.12
$4.081 billion - $4.091 billion (Raised)
$4.23 - $4.26 (Raised)
Mid-single-digit percentage
$10 million - $12 million per quarter
Hedging & Uncertainty: Management used hedging language primarily to set expectations for the timing of future growth rather than to express doubt about the outcome. Phrases like 'we expect to return to slight top line growth' and 'optimistic that we will return to solid mid-single-digit organic revenue growth' indicate confidence in the trajectory while acknowledging the current low base. They used temporal hedges such as 'later in '26, early in '27' regarding new assay launches to manage analyst expectations for immediate contributions. However, the reduction of the tariff guidance from a 'worst case' estimate to a mitigated figure was a move to remove uncertainty rather than introduce it.
We've admittedly hit a few speed bumps in the last couple of quarters, but we view our results as clear evidence of the significant progress we have made. - Stephen P. MacMillan, Chairman, President and CEO
The operative word for Hologic in the third quarter was progress. - Stephen P. MacMillan, Chairman, President and CEO
We are optimistic that we will return to solid mid-single-digit organic revenue growth next year. - Stephen P. MacMillan, Chairman, President and CEO
Through changes to our global supply chain and operating model and various procurement efforts, we expect to mitigate roughly half of the amount we originally provided. - Essex D. Mitchell, Chief Operating Officer
We expect to build on this momentum in the fourth quarter, and we believe we are well positioned to finish the year from a position of strength. - Karleen M. Oberton, Chief Financial Officer
I think we see our Breast Health business being even stronger next year than where we'll even finish this year. - Stephen P. MacMillan, Chairman, President and CEO
It's really for every customer or every lab to have a Fusion capability within the lab. - Karleen M. Oberton, Chief Financial Officer
We've continued to walk away from more things than we're acquiring. - Stephen P. MacMillan, Chairman, President and CEO
Analyst Sentiment: Analysts appeared cautiously optimistic, probing for details on the sustainability of the Breast Health recovery and the specific mechanics of the FY2026 growth algorithm. Questions focused heavily on the 'visibility' of the Q4 rebound and the magnitude of remaining headwinds in China and HIV funding.
Management Responses: Management responses were detailed and data-driven, moving beyond generalities to provide specific figures on tariff mitigation, Endomag sales, and Panther utilization. They effectively deflected concerns about the 'speed bumps' by framing them as past events, using phrases like 'behind us' and 'show me' to acknowledge the need for proof while asserting confidence in the new commercial structure.
Breast Health Recovery: Analysts sought confirmation that the sequential improvement in Q3 would translate to YoY growth in Q4. Management attributed the rebound to a bifurcated sales force, new leadership, and the Endomag acquisition.
FY2026 Outlook: There was significant focus on the 'mid-single-digit' growth target for next year. Management clarified that this excludes COVID and discontinued ops (Fluoroscan) but includes the headwinds from China and HIV funding in the first half.
Tariff Mitigation: Analysts asked for specifics on how the company halved the tariff impact. Management remained vague on specific 'operational efficiencies' for competitive reasons but confirmed the lower run-rate going forward.
China & HIV: Management confirmed the severity of the China decline (>50%) and the reduction in HIV funding, setting a low bar for the first half of FY2026 comparisons.
Hologic appears to be successfully navigating a transition period, with the worst of the Breast Health capital equipment cycle likely in the rearview mirror. The Q3 beat and raise, combined with the successful mitigation of tariff headwinds, demonstrates operational agility and financial discipline. The integration of Endomag ($20M run-rate already) and the upcoming launch of the Envision system in 2026 provide clear catalysts for revenue acceleration. While headwinds in China and Africa persist, the core Diagnostics business remains robust with high Panther utilization, and the international Surgical business is booming. Trading at a valuation that likely discounts the recent stagnation, the stock offers a favorable risk/reward as the company returns to mid-single-digit growth in FY2026. The 'progress' narrative is backed by specific commercial execution improvements and a robust innovation pipeline.
Hologic is experiencing a severe contraction in the Chinese market, with revenue down over 50% YoY to less than $10M. Management attributes this to a 'challenging operating environment' and geopolitical turmoil, noting these headwinds will persist into H1 2026.
Tariffs remain a structural headwind, albeit a mitigated one. The company successfully halved the impact to $10-12M/quarter, but this still represents a ~100 bps drag on gross margins for FY2026 compared to FY2025.
Funding cuts to U.S. aid for HIV testing in Africa are negatively impacting the company's revenue stream in that region, with the business expected to become 'de minimis' in FY2026.
International markets are providing a strong growth offset, particularly in Surgical where revenue grew 24.8%. This is driven by new reimbursement pathways and market expansion, suggesting a successful globalization strategy for women's health products.